Nanjing Leads Biolabs Co (FRA:0DX) Institutional Ownership: 2.17% (As of Aug. 25, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:0DX Nanjing Leads Biolabs Co Ltd FRA:0DX
19 GF Score
Price €7.15
! 1 Warning Sign
View Full Analysis

What is Nanjing Leads Biolabs Co Institutional Ownership?

Nanjing Leads Biolabs Co FRA:0DX -3.38% 19 Institutional Ownership is 2.17% as of Aug. 25, 2026. GuruFocus rates FRA:0DX with a GF Score™ of 19/100. The stock has 1 warning sign investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Nanjing Leads Biolabs Co's institutional ownership is 2.17%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Nanjing Leads Biolabs Co's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Nanjing Leads Biolabs Co's Float Percentage Of Total Shares Outstanding is 0.00%.

Nanjing Leads Biolabs Co Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Nanjing Leads Biolabs Co's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nanjing Leads Biolabs Co Institutional Ownership Chart

Nanjing Leads Biolabs Co Historical Data

The historical data trend for Nanjing Leads Biolabs Co can be seen below:

2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30 2026-07-31
Institutional Ownership 2.19 2.20 2.17 2.10 2.08 2.17 2.17 2.17
FRA:0DX
19GF Score
Nanjing Leads Biolabs Co Ltd FRA:0DX
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nanjing Leads Biolabs Co Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 2.17% mean?
Nanjing Leads Biolabs Co (FRA:0DX) has a Institutional Ownership of 2.17% as of Aug. 25, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Nanjing Leads Biolabs Co and its competitors.
Is Nanjing Leads Biolabs Co's Institutional Ownership too high?
Nanjing Leads Biolabs Co's current Institutional Ownership is 2.17%. Overall, Nanjing Leads Biolabs Co has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Nanjing Leads Biolabs Co's Institutional Ownership compare to VRTX and REGN?
Nanjing Leads Biolabs Co's Institutional Ownership of 2.17% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Nanjing Leads Biolabs Co and its competitors. Nanjing Leads Biolabs Co's current Institutional Ownership is 2.17%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nanjing Leads Biolabs Co stock overvalued right now?
Nanjing Leads Biolabs Co (FRA:0DX) has a current Institutional Ownership of 2.17%. The current Institutional Ownership is 2.17%. Nanjing Leads Biolabs Co's overall GF Score™ is 19/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Nanjing Leads Biolabs Co (FRA:0DX), the current Institutional Ownership is 2.17% as of Aug. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Nanjing Leads Biolabs Co Business Description

Other Exchanges 09887:Hong Kong
Address Jialingjiang Street, 18E, Floor 8, Building 03, Jiangsu Province, Nanjing, CHN, 210019
Nanjing Leads Biolabs Co Ltd is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of new therapies in oncology, autoimmune, and other severe diseases. The Group uses its science-driven R&D approach and three proprietary technology platforms: X-body (4-1BB Engager), LeadsBody (CD3 T Cell Engager), and TOPiKinectics (ADC), for its multi-modal, differentiated pipeline in oncology and autoimmune diseases. It has approximately fourteen drug candidates across oncology and autoimmune diseases. Among these, one core product (LBL-024, a pivotal-stage PD-L1 and 4-1BB dual-targeting bispecific antibody) is being evaluated in several cancer indications and across various Proof-of-Concept (POC) studies. The Group generates maximum revenue from the USA.
19GF Score

Get the complete analysis for FRA:0DX

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€7.15
Price